A U.S. appeals court ruled that Eli Lilly and Co. can block Teva Pharmaceutical Industries Ltd from selling a generic equivalent of its lung cancer drug Alimta.
The U.S. Court of Appeals for the Federal Circuit agreed with a lower court finding that Teva and other defendants would be liable for inducing infringement by doctors who prescribe generic versions of Alimta, according to a Reuters article.
Teva spokeswoman Denise Bradley said the generic drugmaker is disappointed with the decision.
Read the Reuters story